Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Assets (2020 - 2025)

Lyell Immunopharma's Assets history spans 6 years, with the latest figure at $408.0 million for Q3 2025.

  • For Q3 2025, Assets fell 34.12% year-over-year to $408.0 million; the TTM value through Sep 2025 reached $408.0 million, down 34.12%, while the annual FY2024 figure was $490.9 million, 34.55% down from the prior year.
  • Assets for Q3 2025 was $408.0 million at Lyell Immunopharma, up from $385.5 million in the prior quarter.
  • Across five years, Assets topped out at $1.2 billion in Q2 2021 and bottomed at $385.5 million in Q2 2025.
  • The 5-year median for Assets is $815.2 million (2023), against an average of $805.9 million.
  • The largest annual shift saw Assets increased 24.13% in 2021 before it tumbled 41.08% in 2025.
  • A 5-year view of Assets shows it stood at $1.1 billion in 2021, then decreased by 16.84% to $937.6 million in 2022, then dropped by 20.0% to $750.0 million in 2023, then crashed by 34.55% to $490.9 million in 2024, then fell by 16.89% to $408.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Assets are $408.0 million (Q3 2025), $385.5 million (Q2 2025), and $429.8 million (Q1 2025).